Is hyperbaric oxygen or ozone effective in experimental endocarditis?

Ozkan M. T. A. , Vural A., Cicek O. F. , Yener A. U. , ÖZCAN S., Toman H., ...More

JOURNAL OF SURGICAL RESEARCH, vol.202, no.1, pp.66-70, 2016 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 202 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.1016/j.jss.2015.12.006
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.66-70


Background: Infective endocarditis, a disease with high mortality and morbidity, is most commonly caused by Staphylococcus aureus; mortality and morbidity further increase in the presence of methicillin-resistant strains of S. aureus. Linezolid is the first of the oxazolidinones, a new antibiotic group that has been approved for the treatment of infections caused by gram-positive cocci. Linezolid reduces the quantity of microorganisms in vegetation to some extent; in addition, the use of hyperbaric oxygen (HBO) and ozone (O-3) therapies is likely to improve targeted antibacterial effect.